C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
4.260
-0.140 (-3.18%)
At close: Jun 26, 2026, 4:00 PM EDT
4.401
+0.141 (3.31%)
After-hours: Jun 26, 2026, 7:52 PM EDT
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 13.6, with a low estimate of 7.00 and a high estimate of 30. The average target predicts an increase of 219.25% from the current stock price of 4.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for C4 Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $7 | Buy | Maintains | $7 | +64.32% | Jun 22, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $10 | Buy | Reiterates | $10 | +134.74% | May 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 12, 2026 |
| Jefferies | Jefferies | Buy Maintains $14 | Buy | Maintains | $14 | +228.64% | Apr 30, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $7 | Buy | Reiterates | $7 | +64.32% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
18.93M
from 35.95M
Decreased by -47.35%
Revenue Next Year
19.14M
from 18.93M
Increased by 1.14%
EPS This Year
-0.96
from -1.14
EPS Next Year
-1.04
from -0.96
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 29.7M | 29.7M | |
| Avg | 18.9M | 19.1M | |
| Low | 6.0M | 6.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -17.4% | 56.9% | |
| Avg | -47.4% | 1.1% | |
| Low | -83.3% | -68.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.83 | -0.93 | |
| Avg | -0.96 | -1.04 | |
| Low | -1.06 | -1.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.